

Form PTO-1595 (Rev. 01-09)
OMB No. 0651-0027 (exp. 02/28/2009)U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark OfficeRECORDATION FORM COVER SHEET
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies):

ORPEGEN Pharma Gesellschaft für
biotechnologische Forschung,
Entwicklung und Produktion m.b.H.Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies)

Name: Glycotope Biotechnology GmbH

Internal Address: _____

Street Address: _____

Czemyring 22City: Heidelberg

State: _____

Country: Germany Zip: 69115Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s): September 16, 2010☒ Assignment ☐ Merger ☐ Change of Name☐ Security Agreement ☐ Joint Research Agreement☐ Government Interest Assignment☐ Executive Order 9424, Confirmatory License☐ Other _____

4. Application or patent number(s):

A. Patent Application No.(s)

12/655,313☐ This document is being filed together with a new application.

B. Patent No.(s)

5,173,1875,902,7335,403,4886,835,551Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name:

Norman D. Hanson
FULBRIGHT & JAWORSKI L.L.P.Internal Address: Atty. Dkt.: NY-HUBR 1225-US1-CONTStreet Address: 666 Fifth AvenueCity: New YorkState: NY Zip: 10103Phone Number: (212) 318-3168Fax Number: (212) 318-3400Email Address: nhanson@fulbright.com

6. Total number of applications and patents involved:

57. Total fee (37 CFR 1.21(h) & 3.41) \$ 200.00☒ Authorized to be charged to credit card☐ Authorized to be charged to deposit account☐ Enclosed☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Digits 5393Expiration Date 10/2012

b. Deposit Account Number _____

Authorized User Name _____

9. Signature:

Signature

November 24, 2010

Date

Norman D. Hanson - 30,946

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: ☐

Recordation Form Cover Sheet

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-0140, on the date shown below.

Dated: November 24, 2010Signature: Jani Malikouzakis

Jani Malikouzakis

CONFIRMATION OF ASSIGNMENT

ORPEGEN Pharma Gesellschaft für biotechnologische Forschung, Entwicklung und Produktion m.b.H

(ORPEGEN)

a company organized and subsisting under the laws of Germany with an address at Czernyring 22, 69115 Heidelberg, Germany (HRB 334544) is the registered owner of the following patents and patent applications

Process for the regulation of an activated sludge clarification plan
US 5,403,488
Method for control and monitoring of activated sludge in a biological clarification system
US 5,173,187
Test system for determining the activity of natural killer cells
DE 596 04 894.7 (national part of EP 0 830 599)
GB (national part of EP 0 830 599)
US 5,002,733
JP P3190350
Basophil degranulation test
DE 597 06 342.8 (national part of EP 0 874 050)
US 6,835,561
Diagnostic agent for chemotaxis
DE 100 80 880.9
EP 1 259 811
EP 2 211 179
US 10/204,318
US 12/655,313

Furthermore, ORPEGEN is the registered owner of the following German trademarks:

Trademark	Registration Number
PHAGOTEST	1 163 018
PHAGOBURST	2 009 061
LDLReceptorTEST	385 33 147
NKTEST	395 37 924
BASOTEST	397 07 870
MIGRATEST CHEMOTAXIS	301 13 781

ORPEGEN

9-16-2010

Glycotope

PATENT

FROM Koenig-Szynka-Tilman-von Renesse (DUS) (Fre) Nov 19 2010 14:39/ST. 14:39/NO. 8435973151 P 4

2

MIGRATEST	301 13 780
THROMBORETIC	302 08 096
THROMBODIFF	302 08 095
THROMBOMARK	302 08 094
THROMBOCOUNT	302 08 093
THROMBOCHECK	302 08 092
THROMBOSELECT	302 08 091
THROMBOKIT	302 08 090
THROMBOTEST	302 08 089
THROCYTEST	302 21 912
THROMBOCYTEST	304 10 980

Glycotope Biotechnology GmbH


(Glycotape)

a company organized and subsisting under the laws of Germany with an address at Czernyring 22, 69115 Heidelberg, Germany (HRB 704390) has acquired the entire right, title and interest in and to the above mentioned patents, patent applications and trademarks from ORPEGEN with contract signed May 21, 2008.

ORPEGEN hereby declares and confirms that it has assigned the full exclusive rights in and to said above listed patents, patent applications and the inventions covered by said patent rights, and to said above listed trademarks to Glycotope and that Glycotope shall be registered as new owner.

Date, place


Sept. 16, 2010, Heidelberg


Name: Prof. Dr. Christian Birn
Function: President & CEO

ORPEGEN Pharma Gesellschaft für biotechnologische Forschung, Entwicklung und Produktion mbH

Date, place

01.10.10, Berlin


Name:
Function:

Glycotope Biotechnology GmbH

PATENT